Composition and method for treating inflammatory diseases
First Claim
Patent Images
1. A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) which comprises the amino acid sequence of SEQ ID NO:
- 2 with a constant domain of a heavy or light chain of human immunoglobulin at the amino-terminus of said IL-1ra, wherein said fusion protein is produced by a prokaryotic cell.
1 Assignment
0 Petitions
Accused Products
Abstract
A protein which exhibits a therapeutic effect on inflammation and is useful for treating IL-1-mediated inflammatory diseases, particularly diseases of the joint.
90 Citations
16 Claims
-
1. A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) which comprises the amino acid sequence of SEQ ID NO:
- 2 with a constant domain of a heavy or light chain of human immunoglobulin at the amino-terminus of said IL-1ra, wherein said fusion protein is produced by a prokaryotic cell.
- View Dependent Claims (2, 3, 4, 5, 6, 15)
-
7. A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) which comprises the amino acid sequence of SEQ ID NO:
- 2 with a constant domain of a heavy or light chain of human immunoglobulin at the amino-terminus of said IL-1ra, wherein said fusion protein is produced by a mammalian cell.
- View Dependent Claims (8, 9, 10, 11, 12, 13)
-
14. A fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) which comprises:
-
(a) the amino acid sequence of SEQ ID NO;
2;
or(b) an IL-1 inhibitory fragment of the amino acid sequence of SEQ ID NO;
2 in which 1 to 30 amino acids are deleted from the N-terminus or C-terminus,with a constant domain of a heavy or light chain of human immunoglobulin at the amino-terminus of said IL-1ra.
-
-
16. A pharmaceutical composition comprising an effective amount of a fusion protein comprising an interleukin-1 receptor antagonist (IL-1ra) which comprises the amino acid sequence of SEQ ID NO:
- 2 with a constant domain of a heavy or light chain of human immunoglobulin at the amino-terminus of said IL-1ra, and an aqueous pharmaceutically acceptable carrier.
Specification